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Non-major bleeding with apixaban versus warfarin
in patients with atrial ﬁbrillation
M Cecilia Bahit,1 Renato D Lopes,2 Daniel M Wojdyla,2 Claes Held,3 Michael Hanna,4
Dragos Vinereanu,5 Elaine M Hylek,6 Freek Verheugt,7 Shinya Goto,8
John H Alexander,2 Lars Wallentin,3 Christopher B Granger2
ABSTRACT
Objective We describe the incidence, location and
management of non-major bleeding, and assess the
association between non-major bleeding and clinical
outcomes in patients with atrial ﬁbrillation (AF) receiving
anticoagulation therapy enrolled in Apixaban for
Reduction in Stroke and other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE).
Methods We included patients who received ≥1 dose
of study drug (n=18 140). Non-major bleeding was
deﬁned as the ﬁrst bleeding event considered to be
clinically relevant non-major (CRNM) or minor bleeding,
and not preceded by a major bleeding event.
Results Non-major bleeding was three times more
common than major bleeding (12.1% vs 3.8%). Like
major bleeding, non-major bleeding was less frequent
with apixaban (6.4 per 100 patient-years) than warfarin
(9.4 per 100 patient-years) (adjusted HR 0.69, 95% CI
0.63 to 0.75). The most frequent sites of non-major
bleeding were haematuria (16.4%), epistaxis (14.8%),
gastrointestinal (13.3%), haematoma (11.5%) and
bruising/ecchymosis (10.1%). Medical or surgical
intervention was similar among patients with non-major
bleeding on warfarin versus apixaban (24.7% vs 24.5%).
A change in antithrombotic therapy (58.6% vs 50.0%)
and permanent study drug discontinuation (5.1% (61) vs
3.6% (30), p=0.10) was numerically higher with warfarin
than apixaban. CRNM bleeding was independently
associated with an increased risk of overall death
(adjusted HR 1.70, 95% CI 1.32 to 2.18) and subsequent
major bleeding (adjusted HR 2.18, 95% CI 1.56 to 3.04).
Conclusions In ARISTOTLE, non-major bleeding was
common and substantially less frequent with apixaban
than with warfarin. CRNM bleeding was independently
associated with a higher risk of death and subsequent
major bleeding. Our results highlight the importance of
any severity of bleeding in patients with AF treated with
anticoagulation therapy and suggest that non-major
bleeding, including minor bleeding, might not be minor.
Trial registration number NCT00412984;
post-results.
Atrial ﬁbrillation (AF) is an important risk factor
for stroke. Anticoagulation is highly effective in
reducing thromboembolic events; however, bleed-
ing complications are common in this setting.
Although warfarin reduces the risk of stroke in
patients with AF by 64%,1 there is a risk of bleed-
ing that may relate in part to its narrow therapeutic
window and difﬁculties in adjusting dosing.2
Non-vitamin K oral anticoagulants (NOACs) are
effective alternatives to warfarin due to their
proven efﬁcacy in reducing stroke and thrombo-
embolic events and safer proﬁle.3–5 In the
Apixaban for Reduction in Stroke and other
Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) trial,3 apixaban compared with war-
farin signiﬁcantly reduced the risk of stroke, major
bleeding, intracranial haemorrhage and death in
patients with AF.6 In addition, it has been found
that major bleeding was associated with substan-
tially increased risk of death, ischaemic stroke or
myocardial infarction, especially following intracra-
nial haemorrhage.7
However, the relevance and importance of pre-
venting non-major bleeding are less clear. In the
present study, we sought to characterise non-major
bleeding events and their management, and to
evaluate the association between non-major bleed-
ing and subsequent clinical outcomes.
METHODS
The ARISTOTLE trial design and results have been
reported previously.3 8 Patients with AF and at least
one risk factor for stroke were randomised to
receive either dose-adjusted warfarin (international
normalised ratio (INR) 2–3) or apixaban 5 mg
twice daily. A reduced dose of apixaban, 2.5 mg
twice daily, was designated for participants with
two or more of the following criteria: age
≥80 years, weight ≤60 kg or serum creatinine con-
centration ≥1.5 mg/dL (133 mmol/L). In the overall
trial population, the reduced dose of apixaban (or
placebo) was administered to 831 patients (4.7%).
To enhance the quality of warfarin management, a
dosage algorithm was provided and regular feed-
back was provided to sites regarding their level of
INR control. Speciﬁcally, patients were excluded
with conditions other than AF that required antic-
oagulation (eg, a prosthetic heart valve), stroke
within the previous 7 days, a need for aspirin at a
dose >165 mg a day, or a need for both aspirin
and clopidogrel. Approval by the appropriate ethics
committees was obtained at all sites. All patients
provided written informed consent.
Study population
For the purpose of this study, we included all
patients receiving at least one dose of study drug.
Three groups of patients were identiﬁed: patients
with no bleeding, patients in whom the ﬁrst
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bleeding event was clinically relevant non-major or minor and
patients in whom the ﬁrst bleeding event was major. The analyses
of bleeding events included all events from the time of the ﬁrst
dose of study drug until 2 days after the last dose was received.
Bleeding deﬁnitions
Non-major bleeding was the composite of bleeding events con-
sidered to be (a) clinically relevant non-major bleeding or (b)
minor bleeding. Major bleeding was deﬁned according to
International Society on Thrombosis and Haemostasis criteria as
clinically overt bleeding accompanied by a decrease in the
haemoglobin level of at least 2 g/dL or requiring a transfusion
of at least 2 units of packed red blood cells, occurring at a crit-
ical site (intracranial, intraocular, intraspinal, intra-articular,
intramuscular with compartment syndrome, pericardial, retro-
peritoneal), or resulting in death.9
Clinically relevant non-major bleeding was deﬁned as acute
or subacute clinically overt bleeding that did not satisfy the cri-
teria for major bleeding and led to hospital admission for bleed-
ing, physician-guided medical or surgical treatment for bleeding,
or a change in antithrombotic therapy (including study drug)
due to bleeding. All acute clinically overt bleeding events not
meeting the criteria for either major or clinically relevant non-
major bleeding were classiﬁed as minor bleeding. Laboratory
and transfusion data coupled with clinical event details were
used to identify and adjudicate potential bleeding events.
Routine collection of haemoglobin occurred every 3 months.
Location of bleeding was extracted from the case report form.
Additional source documents were collected when necessary.
The primary safety outcomes were adjudicated on the basis of
prespeciﬁed criteria by a clinical events committee whose
members were not aware of study group assignments.
Statistical analysis
Baseline characteristics were presented for patients according to
no bleeding, non-major bleeding and major bleeding.
Continuous variables were summarised as medians and quartiles
and categorical variables as frequencies and percentages.
All-cause mortality and ischaemic stroke after the bleeding
events were analysed using a Cox proportional model with sep-
arate time-dependent variables for bleeding (intracranial, major
non-intracranial, clinically relevant non-major and minor). The
following variables were included in the adjusted results: type of
AF; age; sex; region; history of myocardial infarction; congest-
ive heart failure; stroke, transient ischaemic attack, or systemic
embolism; diabetes; time with AF; hypertension; history of
bleeding; prior vitamin K antagonist (VKA) use; CHADS2
score; history of vascular disease; creatinine clearance; angioten-
sin converting enzyme inhibitors, angiotensin II receptor block-
ers, or amiodarone at randomisation; and randomised
treatment. Kaplan-Meier curves were used to summarise the
incidence of non-major bleeding by randomised treatment. All
analyses were performed with SAS V.9.4 (SAS Institute, Cary,
North Carolina, USA).
RESULTS
Non-major bleeding was three times more common than major
bleeding (12.1% (2204) vs 3.8% (692)). Non-major bleeding
was less frequent with apixaban (6.4 per 100 patient-years) than
warfarin (9.4 per 100 patient-years) (HR (apixaban vs warfarin)
0.69, 95% CI 0.63 to 0.75) (ﬁgure 1).
Baseline characteristics
Baseline characteristics for patients with no bleeding, non-major
bleeding and major bleeding are shown in table 1.
Patients with non-major bleeding had higher risk features
compared with patients with no bleeding, but lower than those
who suffered major bleeding ﬁrst. Mean CHA2DS2-VASc scores
(standard deviation) for patients with no bleeding, non-major
bleeding and major bleeding were 3.4 (1.5), 3.6 (1.5) and 3.8
(1.5), respectively. Renal dysfunction (mild and moderate
impairment) was more common with more severe bleeding. Use
of aspirin was similar in the three groups, but clopidogrel and
non-steroidal anti-inﬂammatory agent use was higher in those
with non-major and major bleeding compared with those with
no bleeding. History of anaemia was almost twice as frequent in
patients with non-major and major bleeding.
Location of haemorrhage
Overall, the most frequent sites of non-major bleeding were
haematuria (16.4%), epistaxis (14.8%), gastrointestinal bleeding
(13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%)
Figure 1 Cumulative incidence
curves of ﬁrst non-major bleeding
event by treatment.
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(ﬁgure 2A); these locations account for 69% of total non-major
bleeding. For each location, bleeding was numerically lower for
apixaban compared with warfarin except for lower gastrointes-
tinal bleeding (ﬁgure 2B). Lower gastrointestinal bleeding and
haemorrhoidal bleeding appeared to be more common with
apixaban compared with warfarin; however, upper gastrointes-
tinal bleeding appeared to be more common with warfarin.
Characteristics and circumstances of ﬁrst non-major
bleeding event
Of the patients with non-major bleeding, in general, medical or
surgical consultations and interventions were similar among
those treated with apixaban versus warfarin (table 2).
Hospitalisations for non-major bleeding events were slightly
more frequent in patients treated with warfarin versus apixaban
(13.8% (178) vs 12.9% (118)). Of those who suffered non-
major bleeding, change in antithrombotic therapy (58.6% (754)
vs 50.0% (459), p<0.0001) and permanent study drug discon-
tinuation (5.1% (61) vs 3.6% (30), p=0.10) were also numeric-
ally higher with warfarin than apixaban.
Association between different severity of bleeding and
subsequent clinical outcomes
Associations between different severity of bleeding and subse-
quent outcomes are shown in ﬁgure 3. Clinically relevant non-
major bleeding was associated with an increased risk of overall
death (adjusted HR 1.70, 95% CI 1.32 to 2.18) to a lower
extent than major non-intracranial bleeding (adjusted HR 2.34,
95% CI 1.84 to 2.99), but to a higher extent than minor bleed-
ing (adjusted HR 1.12, 95% CI 0.90 to 1.40). Among patients
with non-major bleeding, subsequent 30-day mortality was
greater among patients who stopped (10.2%) than those who
continued (4.9%) their anticoagulant study drug (HR 2.1, 95%
CI 1.4 to 3.1). There was also an association between different
severities of bleeding and subsequent ischaemic stroke that did
not reach statistical signiﬁcance.
After multivariable adjustment, minor bleeding and clinically
relevant non-major bleeding were associated with an increase in
subsequent major bleeding (adjusted HR 1.53, 95% CI 1.19 to
1.97 and adjusted HR 2.18, 95% CI 1.56 to 3.04, respectively).
There was a non-signiﬁcant association between non-major
bleeding and minor bleeding and intracranial haemorrhage
(adjusted HR 1.68, 95% CI 0.73 to 3.83 and adjusted HR 1.14,
95% CI 0.61 to 2.12, respectively).
DISCUSSION
In the ARISTOTLE trial, non-major bleeding was more
common than major bleeding and occurred less frequently with
apixaban than warfarin. When non-major bleeding occurred,
apixaban was less frequently discontinued than warfarin.
Minor bleeding was associated with higher risks of ischaemic
stroke, death and subsequent major bleeding. Importantly, clin-
ically relevant non-major bleeding was independently associated
with a signiﬁcant 2.18-fold higher risk of major bleeding and
1.7-fold higher risk of death. The increased risk of major bleed-
ing and death following clinically relevant non-major bleeding
should be interpreted with caution when making decisions in
clinical practice about treatment options because it was derived
from a time-dependent analysis based on information collected
during the study and not on routine clinical practice.
The observation that non-major bleeding was three times
more common than major bleeding was similar to other AF
trials testing new oral anticoagulants. In the Rivaroxaban once
Daily Oral Direct Factor Xa Inhibition Compared with Vitamin
K Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation (ROCKET AF) trial,5 the primary safety end-
point included both major and clinically relevant non-major
bleeding. Clinically relevant non-major bleeding accounted for
most of the events, representing three out of four bleeding
events. In ROCKET AF, 16.7% of the patients treated with
Figure 2 (A) Distribution of most common location of ﬁrst non-major or minor bleeding events (1 patient with missing location; 11 patients had 2
bleeding locations reported); (B) non-major gastrointestinal bleeding location.
Table 2 Characteristics and circumstances of the first clinically
relevant non-major or minor bleeding event according by study drug
Overall
(n=2204)
Apixaban
(n=918)
Warfarin
(n=1286)
Characteristics
Fall in haemoglobin <2 g/dL 268 (12.2) 118 (12.9) 150 (11.7)
Clinically overt 1012 (45.9) 430 (46.8) 582 (45.3)
Lead to transfusion 40 (1.8) 13 (1.4) 27 (2.1)
Required medical or surgical
consultation
1624 (73.7) 723 (78.8) 901 (70.1)
Required medical or surgical
intervention
543 (24.6) 225 (24.5) 318 (24.7)
Caused change in antithrombotic
therapy
1213 (55.0) 459 (50.0) 754 (58.6)
Led to hospitalisation 296 (13.4) 118 (12.9) 178 (13.8)
Circumstances
Spontaneous 1564 (71.0) 638 (69.5) 926 (72.0)
Trauma 529 (24.0) 214 (23.3) 315 (24.5)
Procedure-related 204 (9.3) 100 (10.9) 104 (8.1)
Discontinuations
Permanent 91 (4.4) 30 (3.6) 61 (5.1)
Temporary 527 (25.7) 219 (25.9) 308 (25.5)
Data presented as number (%).
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rivaroxaban and 16.1% of those treated with warfarin experi-
enced clinically relevant non-major bleeding. Clinically relevant
non-major bleeding was deﬁned as overt bleeding not meeting
the criteria for major bleeding but associated with medical inter-
vention, unscheduled contact (visit or telephone call) with a
physician, (temporary) cessation of study treatment, or asso-
ciated with discomfort for the subject such as pain or impair-
ment of activities of daily life. In the randomised evaluation of
long-term anticoagulation therapy (RE-LY), ARISTOTLE and
Effective Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48
(ENGAGE AF-TIMI 48) trials, non-major bleeding was not part
of the primary safety outcome. In RE-LY,4 10 patients with
minor bleeding deﬁned as all other bleeding not fulﬁlling major
or life-threatening bleeding, accounted for 13.6%, 14.8% and
16.3% for dabigatran 110 mg, dabigatran 150 mg and warfarin,
respectively. In ENGAGE AF-TIMI 48,11 clinically relevant non-
major bleeding occurred in 8.7%, 6.6% and 10.2% and minor
bleeding in 4.1%, 3.5% and 4.9% of patients for high-dose
edoxaban, low-dose edoxaban, and warfarin, respectively.
Even though non-major bleeding occurred more frequently,
most of the published analyses concerning prognosis and man-
agement of bleeding have focused on major bleeding.6 7 10 12
Non-major bleeding is clinically important since it is a common
complication and often results in adverse consequences, includ-
ing hospitalisation and cessation of effective anticoagulation that
can lead to worse subsequent clinical outcomes.
In ARISTOTLE,3 non-major bleeding was less frequent with
apixaban than warfarin. This is consistent with the very consist-
ent safety proﬁle of apixaban regarding major bleeding in the
trial.6 The proportions of non-major bleeding according to loca-
tion were similar for apixaban-treated and warfarin-treated
patients. With the exception of lower gastrointestinal bleeding,
apixaban caused less bleeding than warfarin in all other locations.
The increased risk of lower gastrointestinal non-major bleeding
with apixaban, including lower, rectal and haemorrhoidal bleed-
ing, was consistent with the pattern seen in a prior major bleed-
ing analysis of patients taking oral anticoagulants.13 Similar
ﬁndings have been described in the RE-LY study,10 where rates of
overall gastrointestinal major bleeding were higher with both
dabigatran 110 and 150 mg compared with warfarin (1.4%,
1.9% vs 1.3%). Lower gastrointestinal major bleeding was almost
twice as high with dabigatran versus warfarin (47% vs 25%). In
ROCKET AF,12 major or clinically relevant non-major gastro-
intestinal bleeding, including upper, lower and rectal, was statis-
tically signiﬁcantly increased with rivaroxaban compared with
warfarin (5.5% vs 4.1%, p<0.001). Similar patterns were seen in
the ENGAGE AF-TIMI 48 trial, where gastrointestinal bleeding,
including both upper and lower gastrointestinal locations, was
signiﬁcantly more frequent in patients receiving high-dose edoxa-
ban than warfarin (1.51% vs 1.23%, p=0.03).11 With increased
age, the prevalence of gastrointestinal tract conditions, such as
diverticulosis and angiodysplasia,14 and the risk of related bleed-
ing from affected areas increases and when coupled with the
mechanism of action of NOACs15 might help explain the associ-
ation between NOACs and lower gastrointestinal bleeding.
Patients presenting with non-major bleeding who were treated
with apixaban were slightly more likely to require medical or
surgical consultation (78.8%) compared with those treated with
warfarin (70.1%). The reasons for this may include the play of
chance, unblinding of treatment, excessive concern about the
use of a novel anticoagulant like apixaban and lack of knowl-
edge about the management of bleeding with the new oral antic-
oagulants. It is important to note that the rates of bleeding
events are low and that there were fewer patients with bleeding,
regardless of location, in the apixaban-treated group (ﬁgure 3).
Figure 3 Effect of different severities of bleeding on subsequent outcomes (HR (95% CI) for yes vs no). CR, clinically relevant.
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As seen in patients with major bleeding in ARISTOTLE,7 war-
farin treatment was more often associated with surgical inter-
vention and/or change in antithrombotic therapy, as well as
more hospitalisations than apixaban. These ﬁndings reinforce
the safer proﬁle of apixaban compared with warfarin.
The key ﬁndings of the present study are that (a) the inci-
dence of non-major bleeding is high in this population; (b) apix-
aban caused signiﬁcantly less non-major bleeding than warfarin;
and (c) there is an independent increased risk of death and sub-
sequent major bleeding associated with clinically relevant non-
major bleeding, suggesting that physicians should chose the
most efﬁcacious antithrombotic strategy for stroke prevention,
but also balance the risk of bleeding, even if minor.
Limitations
Patients included in ARISTOTLE represent a selected patient
population that likely has a lower risk of bleeding than unse-
lected patients in clinical practice. Thus, rates of non-major
bleeding events may have been underestimated. Many of the
analyses in this manuscript are observational and unmeasured
confounders limit our ability to conclude a cause and effect rela-
tionship between non-major bleeding and clinical outcomes.
Conclusion
In the ARISTOTLE trial, non-major bleeding was common,
associated with adverse outcomes including mortality and subse-
quent major bleeding and was less frequent with apixaban than
warfarin. When non-major bleeding occurred, apixaban was less
frequently discontinued than warfarin. These ﬁndings reinforce
the safer proﬁle of apixaban versus warfarin for patients with
AF, and highlight the importance of any severity of bleeding in
patients with AF treated with anticoagulation therapy, suggesting
that non-major bleeding, including minor bleeding, might not
be minor.
Key messages
What is already known on this subject?
Major bleeding is a marker of worse outcomes in patients with
atrial ﬁbrillation (AF) using oral anticoagulants.
What might this study add?
In our study, non-major bleeding was common, associated with
adverse outcomes including mortality, and was signiﬁcantly less
frequent with apixaban than warfarin.
How might this impact on clinical practice?
Our ﬁndings reinforce the safer proﬁle of apixaban than
warfarin for patients with AF and highlight the importance of
any severity of bleeding in patients with AF treated with
anticoagulation therapy, suggesting that non-major bleeding,
including minor bleeding, might not be minor.
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